The Insights You Need for More of Your Patients
Guardant360 CDx is the first FDA-approved comprehensive liquid biopsy for genomic profiling across all solid tumors and as a companion diagnostic for osimertinib-eligible patients. The recent approval signals a shift in the treatment paradigm to one where a simple blood draw can guide treatment plans for your advanced cancer patients.
Guardant360 CDx quickly delivers the insights needed to personalize treatment—whether at initial presentation, or when your patient is no longer responding to therapy. In 7 days, you receive test results to inform your patients’ treatment plan, avoiding logistical challenges and unnecessary delays associated with tissue biopsy.